Negative diffusion-weighted imaging after intravenous tissue-type plasminogen activator is rare and unlikely to indicate averted infarction.

Available online from MWHC library: 1970 - present, Available in print through MWHC library: 1999 - 2006

BACKGROUND AND PURPOSE: Some patients treated with intravenous (IV) tissue-type plasminogen activator (tPA) have negative diffusion-weighted imaging (DWI) on follow-up imaging. Without a visible infarct, there may be uncertainty as to whether the patient was having a stroke that was averted by tPA or whether the symptoms had not been cerebrovascular in origin. We evaluated patients presenting with suspected acute stroke with a positive DWI lesion before IV tPA to determine the probability of finding a negative DWI up to 48 hours after treatment. CONCLUSIONS: Averted infarction after IV tPA is rare, occurring in 0.9% of patients with pretreatment positive DWI evidence of acute ischemia. For IV tPA-treated patients who have a negative DWI on follow-up imaging, a cause other than acute stroke should be explored. METHODS: We included patients from the Lesion Evolution in Stroke and Ischemia On Neuroimaging (LESION) project who had acute MRI screening with a positive DWI lesion before IV tPA treatment and had follow-up MRI up to 48 hours later. Experienced readers interpreted all acute and follow-up MRIs looking for ischemic lesions on DWI. RESULTS: There were 231 patients who met study inclusion criteria, of which 225 patients (97.4%) had a persistent positive DWI corresponding to the acute stroke lesion on all follow-up imaging. Four patients (1.7%) had transient DWI lesion reversal with positive DWI on subsequent follow-up imaging. There were only 2 cases (0.9%) of complete DWI lesion reversal on all follow-up imaging.


English

0039-2499


*Diffusion Magnetic Resonance Imaging
*Fibrinolytic Agents/tu [Therapeutic Use]
*Stroke/pa [Pathology]
*Stroke/pc [Prevention & Control]
*Tissue Plasminogen Activator/tu [Therapeutic Use]
Adult
Aged
Aged, 80 and over
Cohort Studies
Diagnosis, Differential
Female
Fibrinolytic Agents/ad [Administration & Dosage]
Follow-Up Studies
Humans
Injections, Intravenous
Male
Middle Aged
Retrospective Studies
Stroke/di [Diagnosis]
Thrombolytic Therapy
Tissue Plasminogen Activator/ad [Administration & Dosage]
Treatment Outcome


MedStar Washington Hospital Center


Neurology


Journal Article
Multicenter Study
Research Support, N.I.H., Intramural